Abstract: Described herein are engineered dual binding antibodies that bind to IL-13 and TSLP and uses thereof. Uses include treating allergic and respiratory conditions. Described herein are also libraries comprising the engineered dual binding antibodies, and methods of producing the engineered dual binding antibodies and functional and biochemical characterization of the antibodies.

Abstract: Described herein are method of generating and uses of polypeptides with dual binding specificity, wherein the polypeptides contain a first binding-site for a first antigen and a second binding-site for a second antigen. The second binding-site comprises amino acid variants of native amino acid sequences of polypeptides that bind to the first antigen, wherein the variants do not abrogate binding to said first antigen. In one embodiment, polypeptides with dual binding specificity to PD1 and OX40 are disclosed herein. In another embodiment, polypeptides with dual binding specificity to PD1 and GITR are disclosed herein.

Abstract: Described herein are engineered dual binding antibodies that bind to IL-13 and TSLP and uses thereof. Uses include treating allergic and respiratory conditions. Described herein are also libraries comprising the engineered dual binding antibodies, and methods of producing the engineered dual binding antibodies and functional and biochemical characterization of the antibodies.

Abstract: The present disclosure describes a number of anti-TNFR2 (tumor necrosis factor receptor 2) antibodies. These antibodies are TNFR2 agonists. In certain cases, these antibodies agonize TNFR2 in an Fc independent manner. These antibodies can modulate the proliferation and/or functions of regulatory T cells and myeloid-derived suppressor cells. In certain instances, these antibodies can be used to treat diseases such as GvHD or autoimmune diseases.

Abstract: The present invention is directed to a method for generating a library of antigen binding molecules for screening for binding to an epitope of interest, said method comprising: a. selecting a template antigen-binding molecule from a set of possible template antigen binding molecules wherein said selected template does not specifically bind the epitope of interest but is known to specifically bind another epitope; b. selecting at least one residue position in said template antigen-binding molecule for mutation; and c. selecting at least one variant residue to substitute at the at least one residue position selected in b; such that a library containing a plurality of variants of said template is generated.

Abstract: The present invention is directed to a method for generating a library of antigen binding molecules for screening for binding to an epitope of interest, said method comprising: a. selecting a template antigen-binding molecule from a set of possible template antigen binding molecules wherein said selected template does not specifically bind the epitope of interest but is known to specifically bind another epitope; b. selecting at least one residue position in said template antigen-binding molecule for mutation; and c. selecting at least one variant residue to substitute at the at least one residue position selected in b; such that a library containing a plurality of variants of said template is generated.